Please sign in to follow a disease.
Bladder adenocarcinoma
MONDO:0002751A carcinoma that arises from glandular epithelial cells of the urinary bladder
Also known as: adenocarcinoma of bladder, adenocarcinoma of the bladder, adenocarcinoma of the urinary bladder, adenocarcinoma of urinary bladder, bladder adenocarcinoma, urinary bladder adenocarcinoma, blad
2779 clinical trials for this condition and its sub-types, 5 tagged with Bladder adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Bladder adenocarcinoma
-
Bladder urachal adenocarcinoma 5 trials
-
3 sub-types
-
Bladder mixed adenocarcinoma 1 trial
-
Bladder colloid adenocarcinoma 0 trials
-
Bladder colonic type adenocarcinoma 0 trials
-
Bladder hepatoid adenocarcinoma 0 trials
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New hope for rare cancers: drug combo shows promise in early trial
Disease control Recruiting nowThis phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receiv…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted antibody-drug combo tackle rare bladder cancers?
Disease control Recruiting nowThis phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These …
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC